← Back to Screener
Nutriband Inc. Common Stock (NTRB)
Price$4.20
Favorite Metrics
Price vs S&P 500 (26W)-49.67%
Price vs S&P 500 (4W)1.24%
Market Capitalization$51.13M
All Metrics
Book Value / Share (Quarterly)$0.62
P/TBV (Annual)14.93x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.58%
Cash Flow / Share (Quarterly)$-0.46
Price vs S&P 500 (YTD)-11.42%
Gross Margin (TTM)33.50%
Net Profit Margin (TTM)-560.85%
EPS (TTM)$-1.12
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-1.12
Revenue Growth (5Y)41.99%
EPS (Annual)$-0.99
ROI (Annual)-158.46%
Gross Margin (Annual)34.74%
Net Profit Margin (5Y Avg)-342.73%
Cash / Share (Quarterly)$0.44
Revenue Growth QoQ (YoY)-46.41%
ROA (Last FY)-140.33%
Revenue Growth TTM (YoY)12.69%
EBITD / Share (TTM)$-1.11
ROE (5Y Avg)-78.77%
Operating Margin (TTM)-564.27%
Cash Flow / Share (Annual)$-0.43
P/B Ratio6.77x
P/B Ratio (Quarterly)10.73x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)20.19x
Net Interest Coverage (TTM)-92.02x
ROA (TTM)-158.65%
EPS Incl Extra (Annual)$-0.99
Current Ratio (Annual)4.88x
Quick Ratio (Quarterly)7.07x
3-Month Avg Trading Volume0.02M
52-Week Price Return-16.83%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.60
P/S Ratio (Annual)23.90x
Asset Turnover (Annual)0.29x
52-Week High$11.68
Operating Margin (5Y Avg)-336.53%
EPS Excl Extra (Annual)$-0.99
Tangible BV CAGR (5Y)24.61%
26-Week Price Return-42.78%
Quick Ratio (Annual)4.46x
13-Week Price Return-3.89%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)7.53x
Enterprise Value$45.993
Revenue / Share Growth (5Y)28.04%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)83.77%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.34x
Pretax Margin (Annual)-489.95%
Cash / Share (Annual)$0.39
3-Month Return Std Dev56.31%
Gross Margin (5Y Avg)37.18%
Net Income / Employee (TTM)$-1
ROE (Last FY)-163.05%
Net Interest Coverage (Annual)-89.73x
EPS Basic Excl Extra (Annual)$-0.99
Receivables Turnover (TTM)17.72x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-1.12
Receivables Turnover (Annual)19.23x
ROI (TTM)-180.68%
P/S Ratio (TTM)22.44x
Pretax Margin (5Y Avg)-342.73%
Revenue / Share (Annual)$0.20
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)-51.46%
Year-to-Date Return-7.49%
5-Day Price Return3.45%
EPS Normalized (Annual)$-0.99
ROA (5Y Avg)-67.75%
Net Profit Margin (Annual)-489.95%
Month-to-Date Return18.98%
Cash Flow / Share (TTM)$-0.55
EBITD / Share (Annual)$-0.98
Operating Margin (Annual)-497.91%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-75.42%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-1.12
P/TBV (Quarterly)11.04x
P/B Ratio (Annual)14.32x
Inventory Turnover (TTM)9.96x
Pretax Margin (TTM)-560.85%
Book Value / Share (Annual)$0.58
Price vs S&P 500 (13W)-6.27%
Beta2.05x
Revenue / Share (TTM)$0.19
ROE (TTM)-185.36%
52-Week Low$3.42
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NTRBNutriband Inc. Common Stock | 22.44x | 41.99% | 33.50% | -564.27% | $4.20 |
ISRGIntuitive Surgical Inc. | 16.54x | 18.22% | 66.00% | 29.27% | $465.60 |
EWEdwards Lifesciences Corp | 7.77x | 6.70% | 78.01% | 18.41% | $81.44 |
STESTERIS plc | 3.81x | 12.49% | 44.11% | 17.03% | $226.41 |
ZBHZimmer Biomet Holdings, Inc. | 2.31x | 3.22% | 69.71% | 13.34% | $95.48 |
ALGNAlign Technology Inc | 3.41x | 10.30% | 68.27% | 13.53% | $191.66 |
SNNSmith & Nephew plc | 2.37x | 6.21% | 68.01% | 12.88% | $34.21 |
MSAMine Safety Incorporated | 3.60x | 6.82% | 46.46% | 19.83% | $173.50 |
ESTAEstablishment Labs Holdings Inc. | 9.30x | 20.04% | 69.32% | -18.48% | $66.93 |
ENOVEnovis Corporation | 0.68x | -6.05% | 58.16% | -50.09% | $26.27 |
CDRECadre Holdings, Inc. | 2.19x | 8.57% | 42.54% | 11.04% | $30.51 |
About
Nutriband Inc develops transdermal pharmaceutical products designed to prevent drug abuse and diversion. The company's proprietary AVERSA technology incorporates aversive agents into pharmaceutical formulations to reduce the risk of opioid abuse and misuse. Revenue is generated through the sale of consumer transdermal and coated pharmaceutical products.